Recombinant Mouse SLAMF7 (CRACC/CD319) (carrier-free)

SLAMF7, also knowns as signaling lymphocytic activation molecule family member 7, CRACC, CD319, and leukocyte cell-surface antigen 1 (CS-1), is a cell surface receptor, primarily expressed on immune cells, including NK cell and plasma cells. SLAMF7 is also expressed on dendritic cell, activated monocyte and a subset of T cell. SLAMF7 belongs to SLAM family of receptors, which are involved in regulating immune cell functions and interactions. SLAMF7 possesses an extracellular region comprising of one Ig-like V and one Ig-like C2-set domain, a transmembrane domain and an intracellular domain containing immunoreceptor tyrosine-based switch motif (ITSM). The Ig-like domains mediate interactions with ligands or other receptors, the transmembrane domain anchors the protein in the cell membrane, and the ITSM is responsible for relaying signals to the cell's interior upon ligand binding. The mouse and human SLAMF7 shares 48% amino acid homology. Activation of SLAMF7 occurs by self-ligation of extracellular domain. Upon homophilic receptors activation, downstream signaling modulates NK cell cytolytic activity. SLAMF7 can bind Ewings’s sarcoma-associated transcript 2 (EAT-2) via the ITSM domain leading to the phosphorylation of PLC-γ and PI3K. SLAMF7 expression in myeloma cell is high relative to normal lymphocyte cell subsets which has led multiple investigation of immuno-targeting therapy for multiple myeloma. Upon binding of anti-hSLAMF7 monoclonal antibody, Elotuzumab, to highly-expressed SLAMF7 on myeloma cells, elimination of cancer cells can be by triggered by antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis.